Neonatal hyperbilirubinemia:A clinical analysis of 58 cases

Objective: To observe the causes of hyperbilirubinemia of newborn and to evaluate the clinical effect of medilac-vita combined with ATP, CoA, Vitamin C and Vitamin B₆ on the disease. Methods: Fifty-eight infants with hyperbilirubinemia were randomly divided into two groups:observation group (33 cases) and control group (25 cases). The control group were given luminal and phototherapy, while the observation group were given medilac-vita combined with ATP, CoA, Vitamin C and Vitamin B₆ in addition to the therapy of the control group. The progress of the disease was observed. Results: The response rates were 90.9% and 76.0% in the observation group and the control group respectively. The difference between the two groups was significant (P<0.05). The mean subsiding time for icterus was (4.18±1.41) days and (5.76±3.78) days in observation group and control group respectively (P<0.05);the duration of hospital stay was (8.50±1.52) days and (10.35±2.73) days in observation group and control group respectively (P<0.01). Conclusions: The application of medilac-vita combined with ATP, CoA, Vitamin C and Vitamin B₆ to infants with hyperbilirubinemia can obviously improve the clinical symptom and reduce the hospital stay. It is safe and effective.